About Type-2 angiotensin II receptor
Type-2 angiotensin II receptor (AGTR2) is a protein
from Homo sapiens identified by UniProt accession
P50052, 363 residues long.
MolForge cross-references it against 0 known binders and
378 disease associations.
Target properties
| Protein name | Type-2 angiotensin II receptor |
| UniProt accession | P50052 |
| Gene | AGTR2 |
| Organism | Homo sapiens |
| Length | 363 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (378)
Diseases linked to this target (Open Targets).
- X-linked non-syndromic intellectual disability · score 0.37
- glioblastoma multiforme · score 0.26
- ovarian cancer · score 0.25
- Inguinal hernia · score 0.25
- breast adenocarcinoma · score 0.17
- head and neck squamous cell carcinoma · score 0.16
- neuroinflammatory disorder · score 0.16
- low grade glioma · score 0.14
- postherpetic neuralgia · score 0.09
- neoplasm · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P50052-F1 | alphafold | PREDICTED | 81.99 | — |
Amino-acid sequence (363 residues)
MKGNSTLATT SKNITSGLHF GLVNISGNNE STLNCSQKPS DKHLDAIPIL YYIIFVIGFL VNIVVVTLFC CQKGPKKVSS IYIFNLAVAD LLLLATLPLW ATYYSYRYDW LFGPVMCKVF GSFLTLNMFA SIFFITCMSV DRYQSVIYPF LSQRRNPWQA SYIVPLVWCM ACLSSLPTFY FRDVRTIEYL GVNACIMAFP PEKYAQWSAG IALMKNILGF IIPLIFIATC YFGIRKHLLK TNSYGKNRIT RDQVLKMAAA VVLAFIICWL PFHVLTFLDA LAWMGVINSC EVIAVIDLAL PFAILLGFTN SCVNPFLYCF VGNRFQQKLR SVFRVPITWL QGKRESMSCR KSSSLREMET FVS
Explore Type-2 angiotensin II receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets